Current Issue
VOL 12 NO 4 • MAY/JUN 2021
This issue’s cover illustration depicts ibrutinib binding to cysteine remnants at position Cys 481 on Bruton tyrosine kinase (BTK). BTK is one of the essential enzymes downstream on the BCR signaling pathway. BTK leads to the growth and proliferation of malignant B cells. Targeting the inhibition of BTK has dramatically changed the treatment of B-cell malignancies, including chronic lymphocytic leukemia, mantle cell lymphoma, and marginal zone lymphoma. Artwork by Alexandra Webber Baker © 2021, DNA Illustrations, Inc., Asheville, North Carolina. EditorialBeth Faiman, PhD, MSN, APRN-BC, AOCN®, FAANEvery day, I witness firsthand the amazing things that advanced practitioners and nurse scientists accomplish. Through the conduct of quality improvement (QI) projects and clinical research studies, advanced practitioners and nurse scientists have the opportunity to contribute exponentially not o...
Research and ScholarshipSharyn Carrasco, PhD, RN Patients with cancer experience symptoms from both their disease and treatment, yet clinicians are unaware of 50% to 80% of their patients’ symptoms (Epstein & Street, 2007; Farrell et al., 2001; Ryan et al., 2005). For most cancer patients, symptoms are poorly documented and their impacts ar...
Research and ScholarshipAmanda Hudson Lucas,(1) DNP, RN, ACNS-BC, ACHPN, and Amy Dimmer,(2) DNP, RN, ACCNS-AG A diagnosis of incurable cancer can result in a loss of control and heightened awareness of mortality, necessitating reflection on life’s priorities (García-Rueda et al., 2016). Advance care planning (ACP) discussions represent a patient-centered experience proven to facilitate a review of end-of...
Review ArticleBarbara Barnes Rogers, CRNP, MN, AOCN®, ANP-BC, Carolyn Zawislak, MPAS, PA-C, and Victoria Wong, PA-CImmune checkpoint inhibitors (ICIs) target suppressor receptors, including cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), which are located on the surface of immune cells. Since the activated T cells are not antigen specific, blockade of the immun...
Review ArticleEmily A. Lemke, DNP, AGPCNP-BC, AOCNP®Cancer-related fatigue (CRF) is one of the most prevalent, debilitating symptoms, affecting a majority of cancer patients (up to 99%) worldwide and potentially persisting for up to 10 years after treatment (Gupta et al., 2007; Liu et al., 2012; Neefjes et al., 2013). The National Comprehensive Ca...
Grand RoundsCrystal Flagg, MPAS, PA-C, and Brad Pierce, MPAS, PA-CCase Study
A 15-year-old white female with no significant past medical or surgical history presented to her primary care provider following an episode of collapse without loss of consciousness and with associated symptoms of confusion, dizziness, headache, and vomiting with neurologic symptoms, i...
Practice MattersMegan B. May,(1) PharmD, BCOP, Kate Deen Taucher,(2) PharmD, MHA, BCOP, and Wendy H. Vogel,(3) MSN, FNP, AOCNP®A biosimilar product is highly similar to a U.S. Food & Drug Administration (FDA)-approved biologic product and does not have clinically meaningful differences in regards to safety, purity, and potency (FDA, 2018). Multiple surveys reveal health-care providers have inadequate knowledge about ...
Prescriber's CornerDonald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, and Daniel Thompson,(2) PharmDTargeting the B-cell receptor (BCR) signaling pathway has become an area of interest in the development of pharmacotherapy to treat B-cell malignancies. The BCR pathway plays a role in the growth, proliferation, and survival of normal and malignant B cells (Kenkre & Khal, 2012). One of the es...
